Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial

Santoso, Joseph T.; Lucci, Joseph A.; Coleman, Robert L.; I, Schäfer; Hannigan, Edward V.

doi:10.1007/s00280-003-0620-1

Cited by 191 publications

(148 citation statements)

References 19 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…(14) A third randomized trial of cisplatin at a dose of 75 mg/m 2 and hydration alone, hydration with mannitol, or hydration with furosemide showed that creatinine clearance did not change before or after cisplatin treatment in the hydration alone and the furosemide-treated groups, but decreased in the mannitol-treated group. (15) However, these randomized trials included only small numbers of patients and therefore are not conclusive. Thus, no reports have convincingly shown any advantage of diuretics in preventing cisplatin nephrotoxicity.…”

Section: Discussionmentioning

confidence: 99%

Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity

Sekine¹,

Yamada²,

Nokihara³

et al. 2007

Cancer Science

View full text Add to dashboard Cite

To determine whether bodyweight (BW) loss, daily urine volume (UV) or furosemide use are associated with cisplatin nephrotoxicity, performance status, serum chemistries before treatment, average daily UV, maximum BW loss and use of furosemide on days 1-5 of chemotherapy were evaluated retrospectively in chemotherapy-naive patients with thoracic malignancies who had received 80 mg/m 2 cisplatin. Associations between these parameters and the worst serum creatinine levels (group 1, grade 0 -1; and group 2, grade 2 -3) during the first cycle were evaluated. Of the 417 patients (327 men and 90 women; median age, 59 years), 390 were categorized into group 1 and 27 were categorized into group 2. More women and older patients were observed in group 2 than in group 1 (11.1 vs 5.2%, P = 0.044, and 65 vs 59 years, P = 0.041, respectively). The median average daily UV was 3902 mL in group 1 and 3600 mL in group 2 (P = 0.021). A maximum BW loss ≥ ≥ ≥ ≥2.1 kg was noted in 4.4% of patients in group 1 and 18.5% of patients in group 2 (P = 0.006). Furosemide was used in 206 (49.4%) patients. The median total dose of furosemide in groups 1 and 2 were 0 mg and 26 mg, respectively (P = 0.024). A multivariate analysis showed that a maximum BW loss ≥ ≥ ≥ ≥2.1 kg and the total furosemide dose were significantly associated with group category. In conclusion, BW loss and total furosemide dose were associated with cisplatin nephrotoxicity. (Cancer Sci 2007; 98: 1408-1412) C isplatin alone or in combination with other chemotherapeutic agents has been the most frequently used chemotherapy regimen against a variety of solid tumors for 30 years because of its significant therapeutic effects.(1) In spite of intensive efforts to devise platinum analogs and the successful development of carboplatin, cisplatin remains a key agent in the treatment of germ cell tumors, head and neck cancer and bladder cancer, as shown in several randomized controlled trials comparing the two platinum agents.(2) In addition, cisplatin has a significant role in the treatment of lung and ovarian cancers, although carboplatin is becoming increasingly used against these cancers as an alternative chemotherapeutic agent. (3,4) Cisplatin nephrotoxicity has been a major dose-limiting toxicity for this drug in most drug administration schedules. (5) Although the exact mechanism is unclear, high concentrations of platinum and widespread necrosis were observed in the proximal tubules of the kidney. This tubular impairment secondarily leads to a reduction in renal blood flow and glomerular filtration rate, potentiating primary tubular damage. This vicious circle causes a delayed deterioration in renal function, as an increase in the serum creatinine level typically appears 6-7 days after cisplatin administration in humans.(5,6) The standard prophylaxis for cisplatin nephrotoxicity is a normal saline infusion of 1-4 L with osmotic diuresis on the day of cisplatin administration. (5) Although this vigorous hydration diminishes life-threatening renal toxicity, 7-40% of patients s...

show abstract

Section: Discussionmentioning

confidence: 99%

Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity

Sekine¹,

Yamada²,

Nokihara³

et al. 2007

Cancer Science

View full text Add to dashboard Cite

show abstract

“…[3] Indeed, irreversible renal damage occurs in about one-third of cisplatin-treated patients despite using known prophylactic methods like hydration. [4,5] There is almost a century of literature that supports the concept that prior injury may protect the kidney against a second insult, and it has been shown more recently that the primary stimulus may not necessarily reach the injurious level. [6] For example, sub-lethal short ischemic periods may attenuate subsequent renal functional or structural damage induced by prolonged ischemia.…”

Section: Introductionmentioning

confidence: 99%

Pretreatment with Oxygen Protects Rat Kidney from Cisplatin Nephrotoxicity

et al. 2010

View full text Add to dashboard Cite

Cisplatin (CP) nephrotoxicity is mainly due to reactive oxygen species. Oxygen pre-exposure as a mild oxidative stress may enhance some endogenous defense mechanisms, so its effect on cisplatininduced acute renal failure was investigated in present study.Twenty-four rats were divided into four groups. The O 2 + CP and Air + CP groups were were subjected to i.p. injection of 5 mg/kg cisplatin, and in the Air + Saline and O 2 + Saline groups, saline was injected instead of cisplatin. O 2 + CP and O 2 + Saline groups were pretreated with oxygen (3h/d for two days), and the other two groups were pretreated with room air. Cisplatin was administered 24 h after last pretreatment session. Three days after cisplatin injection, plasma samples were obtained, and parts of kidney tissue were frozen for biochemical analysis or fixed in formalin for histological assessments. Preconditioning with oxygen prior to cisplatin administration led to reduced tubular necrosis and luminal cast formation and improvement of renal function, as was evidenced by significant reduction in plasma creatinine and urea levels. Oxygen pretreatment also significantly reversed cisplatin-induced reduction in renal catalase activity and glutathione level. It could be concluded that oxygen pretreatment could have a delayed protective effect against cisplatin nephrotoxicity, and that increased renal catalase activity may be involved in this protective effect of hyperoxia.

show abstract

“…27 Despite various hydration protocols designed to minimize the nephrotoxicity, approximately one-third of patients who receive cisplatin develop evidence of acute renal failure. 28 Cisplatin accumulates in all nephron cells, but especially in the proximal kidney tubule cells within the S3 segment, which bear the brunt of the damage. 27 We did not observe any case of nephrotoxicity in the patients in the current study, although they had been previously treated with platinum compounds.…”

Section: Discussionmentioning

confidence: 99%

Phase 1 trial of lipoplatin and gemcitabine as a second‐line chemotherapy in patients with nonsmall cell lung carcinoma

Froudarakis

Pataka

Pappas

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND.Lipoplatin is a new liposomal cisplatin that already has been tested in solid tumors, with encouraging results. The purpose of the current study was to determine the maximum tolerated dose (MTD) and the dose‐limiting toxicity (DLT) of a 21‒day regimen of lipoplatin plus a fixed dose of gemcitabine in patients with refractory or resistant nonsmall cell lung carcinoma (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.METHODS.The lipoplatin dose was escalated at 100 mg/m2 by increments of 10 mg/m2 on Days 1 and 8, with gemcitabine at a dose of 1000 mg/m2 administered on Days 1 and 8, repeated every 21 days. Hematopoietic growth factors were not allowed. Thirteen patients with advanced stage NSCLC who had been pretreated with platinum combination chemotherapy were enrolled in this phase 1 trial. At least 3 patients were entered at each dose level.RESULTS.At the fourth dose level, the DLT was reached (grade 3 neutropenia [according to World Health Organization criteria] in 3 of 4 patients 75%]; the fourth patient demonstrated degradation of performance status). Therefore, the third dose level (lipoplatin at a dose of 120 mg/m2) was defined as the MTD. At the same dose level, 2 of 4 patients had grade 3 thrombocytopenia. At the fourth dose level, 1 patient achieved a partial response and 1 patient had stable disease. Another patient achieved stable disease at the second dose level. Therefore, the overall disease control rate was 23% (3 of 13 patients). The median overall survival was 29 weeks (range, 4 weeks‐59 weeks) and the median time to disease progression was 12 weeks (range, 3 weeks‐36 weeks).CONCLUSIONS.The pharmacokinetic profile of the 2 compounds used in the current study are not modified when they are administered according to the schedule evaluated in this trial. When one considers that the patients in the current study had refractory or resistant NSCLC, the authors concluded that the combination of lipoplatin administered at a dose of 120 mg/m2 and gemcitabine administered at a dose of 1000 mg/m2 on Days 1 and 8 every 3 weeks needs to be studied further in phase 2 trials. Cancer 2008. © 2008 American Cancer Society.

show abstract

Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial

Abstract: Hydration with saline or saline + furosemide appears to be associated with less cisplatin nephrotoxicity than saline + mannitol.

Cited by 191 publications

References 19 publications

Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity

Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity

Pretreatment with Oxygen Protects Rat Kidney from Cisplatin Nephrotoxicity

Phase 1 trial of lipoplatin and gemcitabine as a second‐line chemotherapy in patients with nonsmall cell lung carcinoma

Contact Info

Product

Resources

About